Skip to content

Erbium Vaginal Laser for the Treatment of Stress Urinary Incontinence

Erbium Vaginal Laser for the Treatment of Stress Urinary Incontinence - Randomized Single Blind Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04636749
Enrollment
80
Registered
2020-11-19
Start date
2021-03-09
Completion date
2022-10-22
Last updated
2021-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress Urinary Incontinence

Brief summary

Two arms of women who suffer from clinical stress urinary incontinence. Women will be divided randomly into two arms. One arm will be treated with vaginal Erbium laser and the second with Sham laser, three treatments each. Follow up will be done 6 and 12 months after the last treatment.

Detailed description

Examine the efficacy of vaginal Erbium laser treatment for stress urinary incontinence (SUI) in compare to placebo. Plenty of women suffer from SUI. It is a condition in which involuntary urine leakage occurs during exercise. This condition affects about 40% of all women and causes huge disturbance to daily life. There are plenty of risk factors, such as age, obesity and parity. We assume that the pathophysiology is related to hypermobility of the urethra due to damage to the surrounding tissue. The treatment options vary from surgical interventional to conservative, each treatment has its own success rate and risk factors. An attempt to find effective treatment option has been made. The use of laser for various gynecologic conditions are at rise. ERBIUM type laser works on the lamina propria layer and causes rejuvenation probably by strengthening collagen structures and creating new ones. The efficacy and safety of vaginal laser therapy has been proven already, but in the field of SUI the numbers in each study were low and there was no control group. In this study we desire to examine the effect of vaginal ERBIUM treatment on SUI in compare to placebo. this is a randomized single blind control trial. 40 women will be included in the research group and 40 in the placebo group. Women will be assigned randomly to each group. They will be treated with vaginal laser probe, three treatments 4 weeks apart. Follow up visits will be performed 3, 6, and 12 months after the first treatment. Effectiveness evaluation will be done by physical urodynamic examination before treatment and 6 month after finishing, by 24 hours pad test' cough test and by fulfilling questionnaires- 1. The Urogenital Distress inventory (UDI6) 2. The Female Sexual Function Index (FSFI)

Interventions

Vaginal laser therapy

DEVICESham laser

Sham laser therapy

Sponsors

Rambam Health Care Campus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

women above 18 with SUI -

Exclusion criteria

1. Recurrent pelvic inflammatory disease 2. Vaginal operation in the previous year 3. Women with abnormal uterine bleeding 4. Women with diagnosed genital herpes infection 5. Any concurrent lower genital tract infection -

Design outcomes

Primary

MeasureTime frameDescription
Cough testFrom enrollment up to 12 months post treatmentResults of full bladder cough test
Pad testFrom enrollment up to 12 months post treatmentResults of 24 hour pad weighing test

Secondary

MeasureTime frameDescription
Urinary distress index 6From enrollment up to 12 months post treatmentResults of Urinary distress index 6 questionnaire
Female sexual functionFrom enrollment up to 12 months post treatmentResults of female sexual function index questionnaire
Urinary incontinence and sexualityFrom enrollment up to 12 months post treatmentResults of urinary incontinence and sexuality questionnaire

Countries

Israel

Contacts

Primary ContactNaama Farago, MD
n_farago@rmc.gov.il972-509267806

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026